Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 25, 1999

View Archived Issues

Corvas continues development progress during third quarter

AHP updates investors and analysts on R&D progress

Idec completes patient enrollment in two pivotal studies during third quarter

Review of Hectorol Injection NDA back on course

Potassium channel activator SKP-450 has potent antiulcer effects in rat models

Three-year subdermal contraceptive implant marketed in the U.K.

Sanofi-Synthelabo's platinum complex launched in second European market

Wound-healing agent reaches the market in U.K.

Creative BioMolecules funnels resources towards stroke and renal disease therapy

Polyethoxylated retinamides superior to known retinoic acid derivatives for skin aging

Interim phase I/II results presented for Transgene's TG-1021

Preclinical results indicate that nefiracetam may have anticonvulsant effects

News from AAO/PAAO joint meeting: droperidol may be indicated for glaucoma

Cancer immunotherapy method available for licensing from NIH

Alphagan safely and effectively lowers IOP in glaucoma patients

Specific FKBP-12 rotamase inhibitors useful for neurodegenerative disorders

Nonpeptide integrin antagonists from DuPont and use for inhibiting cell adhesion

AHP's new beta3-adrenoceptor agonists presented in patent literature

HepaVec and CSIRO sign option agreement for ovine viral vector technology

New anticoagulants in the pipeline at DuPont

U. of Minnesota designs anticancer, antiviral phosphoramidated nucleosides

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...